Details of the Drug Inactive Ingredient (DIG)

General Information of DIG (ID: E0E7MW)
DIG Name
Poloxamer 407
DIG Function
Emulsifying agent; Solubilizing agent; Surfactant
Full List of Active Pharmaceutical Ingredients (APIs) Co-administrated with This DIG
       ICD Disease Classification 01 Infectious/parasitic disease Click to Show/Hide
Famciclovir
 API Info
Genital herpes [ICD-11: 1A94]
 [1]
Raltegravir
 API Info
Human immunodeficiency virus infection [ICD-11: 1C60]
 [2]
       ICD Disease Classification 05 Endocrine/nutritional/metabolic disease Click to Show/Hide
Fenofibrate
 API Info
Hypertriglyceridaemia [ICD-11: 5C80]
 [3]
Repaglinide
 API Info
Diabetes mellitus [ICD-11: 5A10]
 [4]
       ICD Disease Classification 06 Mental/behavioural/neurodevelopmental disorder Click to Show/Hide
Duloxetine
 API Info
Major depressive disorder [ICD-11: 6A70]
 [5]
       ICD Disease Classification 08 Nervous system disease Click to Show/Hide
Gabapentin
 API Info
Focal seizure [ICD-11: 8A68]
 [6]
       ICD Disease Classification 11 Circulatory system disease Click to Show/Hide
Dronedarone
 API Info
Atrial fibrillation [ICD-11: BC81]
 [7]
       ICD Disease Classification 13 Digestive system disease Click to Show/Hide
Omeprazole
 API Info
Gastro-oesophageal reflux disease [ICD-11: DA22]
 [8]
Aprepitant
 API Info
Functional nausea/vomiting [ICD-11: DD90]
 [9]
       ICD Disease Classification 14 Skin disease Click to Show/Hide
Acitretin
 API Info
Psoriasis vulgaris [ICD-11: EA90]
 [10]
       ICD Disease Classification 15 Musculoskeletal/connective-tissue disease Click to Show/Hide
Raloxifene
 API Info
Osteoporosis [ICD-11: FB83]
 [11]
Full List of Biological Targets of DIG (DBTs) Regulated by This DIG
      Oxidoreductase (ORase)
            DBT Name: Albendazole monooxygenase (CYP3A4) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity EC50 = 32.8 uM (tested by experiment) [12]
                    Tested Species Homo sapiens (Human)
                    UniProt ID CP3A4_HUMAN
            DBT Name: Cytochrome P450 2E1 (CYP2E1) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity IC50 = 218.9 uM (tested by experiment) [12]
                    Tested Species Homo sapiens (Human)
                    UniProt ID CP2E1_HUMAN
            DBT Name: Cytochrome P450 2C9 (CYP2C9) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity EC50 = 355 uM (tested by experiment) [12]
                    Tested Species Homo sapiens (Human)
                    UniProt ID CP2C9_HUMAN
            DBT Name: Debrisoquine 4-hydroxylase (CYP2D6) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity EC50 = 101.6 uM (tested by experiment) [12]
                    Tested Species Homo sapiens (Human)
                    UniProt ID CP2D6_HUMAN
      Cell line (CELL)
            DBT Name: Colon cancer Caco-2 cells (Caco-2) Click to Show/Hide
               Detailed Information DBT Info click to show the detail info of this DBT
               Experiment (1) for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity Inhibition ratio = 38 % (tested by experiment) [13]
                    Tested Species Homo sapiens (Human)
               Experiment (2) for Assessing the Biological Activity of the Studied DIG on This DBT
                    Biological Activity Inhibition ratio > 45 % (tested by experiment) [14]
                    Tested Species Homo sapiens (Human)
References
1 FDA label for approved famciclovir from the official website of the U.S. Food and Drug Administration.
2 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
3 FDA label for approved fenofibrate from the official website of the U.S. Food and Drug Administration.
4 FDA label for approved repaglinide from the official website of the U.S. Food and Drug Administration.
5 FDA label for approved duloxetine from the official website of the U.S. Food and Drug Administration.
6 FDA label for approved gabapentin from the official website of the U.S. Food and Drug Administration.
7 FDA label for approved dronedarone from the official website of the U.S. Food and Drug Administration.
8 FDA label for approved omeprazole from the official website of the U.S. Food and Drug Administration.
9 FDA label for approved aprepitant from the official website of the U.S. Food and Drug Administration.
10 FDA label for approved acitretin from the official website of the U.S. Food and Drug Administration.
11 FDA label for approved raloxifene from the official website of the U.S. Food and Drug Administration.
12 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
13 Inhibition of human efflux transporter ABCC2 (MRP2) by self-emulsifying drug delivery system: influences of concentration and combination of excipients. J Pharm Pharm Sci. 2014;17(4):447-60.
14 Interactions between human multidrug resistance related protein (MRP2; ABCC2) and excipients commonly used in self-emulsifying drug delivery systems (SEDDS). Int J Pharm. 2013 Apr 15;447(1-2):192-8.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.